Song Ruilin: What is the "blocker" in the development of China's pharmaceutical innovation?

Recently, the annual Global Life and Health Conference-2021 New Force Forum was held in Hangzhou International Expo Center
.
At the meeting, Song Ruilin, executive chairman of China Pharmaceutical Innovation Promotion Association, shared the current problems facing China's pharmaceutical innovation and development

Chairman Song Ruilin said that since the establishment of the major national new drug creation project in 2008, policy guidance has been a distinct trend in the development of China’s biomedical industry.
During the period from the 11th Five-Year Plan to the 13th Five-Year Plan, China has invested 23.
3 billion in support.
Thousands of new drug projects.
This initiative has stimulated people's confidence in drug innovation and promoted the investment of social capital.
Between 2015 and 2020, the investment of social capital increased from 12 billion to 185 billion, an increase of 15 times
.
 

Chairman Song Ruilin believes that the current medical innovation in China, especially the innovation of oncology drugs, has ushered in new changes.
The five-year survival rate of non-small cell lung cancer has increased from 30% to 40%, which is a significant improvement
.
At the same time, the innovation capabilities of local pharmaceutical companies have been increasingly recognized internationally, and more and more products have moved to the accelerated approval channel of the US FDA

Opportunities and challenges always accompany
.
Chairman Song Ruilin emphasized that in the future, China's pharmaceutical innovation will face greater challenges while welcoming more opportunities